Stockreport

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Kairos Pharma, Ltd.  (KAPA) 
PDF Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to [Read more]